Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
52
Views
14
CrossRef citations to date
0
Altmetric
Case Report

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report

Linghui DengDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China
,
Yue WangDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China
,
Wenbin LuDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China
,
Qian LiuDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China
,
Jie WuDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China
&
Jianhua JinDepartment of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of ChinaCorrespondence[email protected]
Pages 1521-1525 | Published online: 13 Mar 2017

References

  • TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
  • StuartGCKitchenerHBaconMparticipants of 4th Ovarian Cancer Consensus Conference (OCCC)Gynecologic Cancer Intergroup2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus ConferenceInt J Gynecol Cancer201121475075521543936
  • JaysonGCKohnECKitchenerHCLedermannJAOvarian cancerLancet201438499511376138824767708
  • PerrenTJSwartAMPfistererJICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
  • BurgerRABradyMFBookmanMAGynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
  • AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
  • Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
  • OzaAMCookADPfistererJICON7 trial investigatorsStandard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialLancet Oncol201516892893626115797
  • LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
  • LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
  • MiYJLiangYJHuangHBApatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersCancer Res201070207981799120876799
  • LedermannJAEmbletonACRajaFICON6 collaboratorsCediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trialLancet2016387100231066107427025186
  • LiXFTanYNCaoYXuJHZhengSYuanYA case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancerMedicine (Baltimore)20159439e166126426663

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.